Compare FBYD & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | VALN |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.0M | 855.8M |
| IPO Year | N/A | 2021 |
| Metric | FBYD | VALN |
|---|---|---|
| Price | $6.70 | $9.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 122.8K | 19.7K |
| Earning Date | 11-14-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $9,673,000.00 | ★ $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | $1,627.16 | ★ N/A |
| Revenue Growth | ★ 28.46 | 13.48 |
| 52 Week Low | $3.62 | $4.71 |
| 52 Week High | $29.02 | $12.25 |
| Indicator | FBYD | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 51.95 |
| Support Level | $5.81 | $9.20 |
| Resistance Level | $7.59 | $10.32 |
| Average True Range (ATR) | 1.35 | 0.32 |
| MACD | -0.34 | -0.05 |
| Stochastic Oscillator | 15.89 | 35.90 |
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.